Syncope in children and adolescents

Khalil Kanjwal, Hugh Calkins

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Most strategies for managing syncope in children reflect data from studies involving the adult population. In the future, there will be a great need for studies in children and adolescents suffering from recurrent syncope. To date, there has been no Food and Drug Administration-approved therapy for neurocardiogenic syncope (NCS), the most common cause of syncope in both adults and children. None of the clinical trials of pharmacotherapy in NCS has shown benefit over placebo. NCS should be considered a chronic condition, and the aim of the therapy should be to decrease recurrence of syncope rather than to completely eliminate it.

Original languageEnglish (US)
Pages (from-to)443-455
Number of pages13
JournalCardiac Electrophysiology Clinics
Issue number4
StatePublished - Dec 2013


  • Adolescents
  • Children
  • Neurocardiogenic syncope
  • Syncope

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Syncope in children and adolescents'. Together they form a unique fingerprint.

Cite this